120202-69-9

Basic information

• Product Name: Clopidogrel Impurity C
• Synonyms: methyl (R)-2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetate
• CAS NO: 120202-69-9
• Molecular Formula: C₁₆H₁₆ClNO₂S
• Molecular Weight: 321.82
• Mol File: 120202-69-9.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Clopidogrel Impurity C(CAS DataBase Reference)
• NIST Chemistry Reference: Clopidogrel Impurity C(120202-69-9)
• EPA Substance Registry System: Clopidogrel Impurity C(120202-69-9)

Safety Data

• Hazardous Substances Data: 120202-69-9(Hazardous Substances Data)

Usage

General Description

Clopidogrel Impurity C is a pharmaceutical compound that is used as a reference standard in the analysis of clopidogrel, a medication used to prevent blood clots. It is a known impurity in the synthesis of clopidogrel and can be used to assess the quality and purity of the final product. Clopidogrel Impurity C is also used for research and development purposes, particularly in the pharmaceutical industry, to study the pharmacological and toxicological properties of clopidogrel and its related compounds. Its characterization and quantification are essential for the quality control and regulatory compliance of clopidogrel products.

Upstream product

• 10421-85-9 (R)-2-chloromandelic acid 
• 28783-41-7 6,7-dihydro-4H-thieno[3,2-c]pyridine hydrochloride 
• 90055-48-4 clopidogrel 
• 847986-65-6 (R)-(-)-camphorsulphonic scid salt of methyl (R)-(-)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate 
• 67-56-1 methanol 
• 35963-20-3 (R)-10-camphorsulfonic acid 
• 929200-24-8 sodium (R)-(2-chlorophenyl)-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)-acetate 
• 77-78-1 dimethyl sulfate 

Downstream Products

• 929200-19-1 sodium (+/-)-(2-chlorophenyl)-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)-acetate 
• 90055-48-4 clopidogrel 
• 120202-71-3 methyl (S)-(+)-2-(2-chlorophenyl)-2-(6,7-dihydrothieno-[3,2-c]pyridin-5(4H)-yl)acetate bisulfate 
• 929200-21-5 (+/-)-(2-chlorophenyl)-(4,5,6,7-4H-thieno[3,2,-c]pyrid-5-yl) potassium acetate 
• 120202-66-6 (S)-(+)-clopidogrel bisulfate 

Relevant articles and documents

Method for recycling S - O-chloromandelic acid

The invention belongs to the technical field of chemical synthesis, and discloses a method for recycling S-o-chloromandelic acid. The o-chloromandelic acid is a clopidogrel hydrogen sulfate starting material. The method is characterized by comprising the following steps: concentrating a lipid solution of S-o-chloromandelic acid to dryness, and adding an alkaline aqueous solution to react at a hightemperature to racemize the S-o-chloromandelic acid; after the reaction is completed, adding a C2-C8 lipid solvent and adjusting the pH of the solution with an inorganic acid to be acidic; separatingan aqueous phase from an organic phase, and allowing the organic phase to be dried and directly reacted with a resolving agent to prepare R-o-chloromandelic acid. The invention provides a method forrecycling clopidogrel hydrogen sulfate intermediate waste, the influence of reaction byproducts on the environment is eliminated, the S-o-chloromandelic acid is converted and then used in the preparation process of clopidogrel hydrogen sulfate, and the economic value is very high.

RACEMIZATION PROCESS FOR THE PREPARATION OF AN INTERMEDIATE OF CLOPIDOGREL HYDROGEN SULPHATE

The invention relates to a process for the preparation of the pharmaceutically applicable methyl (S)-(+)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)- acetate hydrogen sulphate (also known as S-(+)-clopidogrel hydrogen sulphate) of formula (I) comprising racemizing methyl (R)-(-)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine- 5(4H)-acetate or methyl (S)-(+)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)- acetate, or a mixture thereof in any proportion with a weak base in the presence of an organic solvent, converting the methyl (R,S)-(±)-α-(2-chlorophenyl)-6,7-dihydrothieno [3,2-c]pyridine-5(4H)-acetate of fomula (II) obtained to its sulphuric acid addition salt methyl (R,S)-(±)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate hydrogen sulphate and converting it to methyl (S)-(+)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c] pyridine-5(4H)-acetate hydrogen sulphate of formula (I) by known manner.

Process for preparing clopidogrel

The present invention encompasses processes for the preparation of optically pure clopidogrel camphorsulfonic acid salt without the need to isolate or recover (±) clopidogrel.